NASDAQ$GNLX
Genelux Corporation · Q4 2026 earnings
Q4 2026 earnings · · After market close · Investor relations
Briefing
Genelux Corporation reported Q4 fiscal 2026 with no product revenue and a net loss of $8.9M, or $0.20 per share.
For the quarter ended March 31, 2026, Genelux reported no revenue and a net loss of $8.9 million, or $0.20 per diluted share, compared with a $7.5 million loss and $0.21 per share a year ago. R&D expense was $5.8 million as the oncology biotech advances clinical programs.
- No product revenue; net loss $8.9M, or $(0.20) per share.
- R&D $5.8M; pre-commercial oncology development stage.
Headline financials
Revenue & EPS history
Genelux · Revenue · Quarterly
$0
Forward guidance
Clinical-stage biotech; financing and trial milestones discussed, no product revenue guidance.
Tailwinds
- Operating loss in line with development-stage peers.
Headwinds
- Dependent on capital markets for funding without product sales.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 16 quarterly earnings reports · overlaid with Q4 2026
-4.7%
Avg return
Earnings day
-5.1%
Avg return
5 days after
-0.7%
Avg return
30 days after
31%
5 / 16 earnings
Positive
+4.7%
Q2 2023
Best reaction
-31.4%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -6.9% | +12.1% | +3.9% | |
| Q3 2025 | -31.4% | -23.7% | -40.8% | |
| Q2 2025 | -6.0% | -4.2% | +0.9% | |
| Q1 2025 | +4.5% | +0.4% | +30.2% | |
| Q4 2024 | -4.4% | -11.5% | -10.2% | |
| Q3 2024 | -16.0% | -11.7% | -17.1% | |
| Q2 2024 | +3.4% | +1.5% | +18.4% | |
| Q1 2024 | +1.1% | -5.5% | -39.8% | |
| Q4 2023 | -18.4% | -23.3% | -49.0% | |
| Q3 2023 | -4.8% | -16.2% | +4.6% | |
| Q3 2022 | -4.8% | -16.2% | +4.6% | |
| Q2 2022 | +4.7% | +3.6% | -8.6% | |
| Q2 2023 | +4.7% | +3.6% | -8.6% | |
| Q4 2022 | -0.4% | +3.4% | +33.6% | |
| Q1 2022 | -0.4% | +3.4% | +33.6% | |
| Q1 2023 | -0.4% | +3.4% | +33.6% | |
| Q4 2021 | — | — | — | |
| Q3 2021 | — | — | — | |
| Q2 2021 | — | — | — | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro